Know Cancer

forgot password

Combination Targeted Radiotherapy in Neuroendocrine Tumors

18 Years
Open (Enrolling by invite only)
Neuroendocrine Tumors

Thank you

Trial Information

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Inclusion Criteria:

- Subjects with biopsy-proven metastatic (soft tissue) neuroendocrine tumors.

- Subjects with a Southwest Oncology Group (SWOG) performance score of 0-2 and an
expected median survival of at least 6 months.

- The subject is able and willing to comply with study procedures and a signed and
dated informed consent is obtained.

- Subjects must be >18 years of age

Exclusion Criteria:

- Subjects who use medications that are known to interfere with MIBG uptake and is
unable to discontinue for medical reasons.

- Prior chemotherapy, radiotherapy or any investigational drugs within 60 days prior
admission into this study. Patients must have recovered from all therapy-related

- Renal insufficiency with a serum creatinine > 2mg/dl.

- Subjects unable to lie still for the imaging studies.

- Subjects who because of their weight and body distribution do not fit into the
imaging machine.

- Subjects receiving Sandostatin LAR < 21 days prior to dosing or Sandostatin Immediate
Release (IR) < 24 hours prior to dosing.

- Female patients who are pregnant or breast feeding. Women of childbearing potential
must have a negative serum/urine pregnancy test within 48 hours prior to
administration of study treatment.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Dosimetry Results

Outcome Description:

Determine the patient specific bone marrow, kidney and tumor dosimetry results for each subject from the 2 groups will be used to calculate the optimal combination of administered activities for 131I-MIBG plus 90Y-DOTATOC (group 1) 131I-MIBG plus 177Lu-DOTATATE (group 2) and the resultant dose delivery to tumor from each combination

Outcome Time Frame:

1 week after scan

Safety Issue:


Principal Investigator

David Bushnell, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Iowa; Veteran Affairs


United States: Federal Government

Study ID:




Start Date:

March 2007

Completion Date:

December 2013

Related Keywords:

  • Neuroendocrine Tumors
  • Neuroendocrine Tumor
  • Imaging
  • Neuroendocrine Tumors



University of IowaIowa City, Iowa  52242
Department of Veteran Affairs Medical CenterIowa City, Iowa  52246